OBJECTIVES: Understanding HSUV and HRQoL post-antiretroviral therapy (post-ART) is important to PLWH, the physicians who manage them and policy makers. Therefore, we conducted an SLR to identify HSUVs and HRQoL in PLWH and to understand the impact of their sociodemographic factors.

METHODS: Embase, MEDLINE and MEDLINE In-Process were searched from inception to November 5^th, 2021, supplemented by hand-searching of conferences published from 2019-2021 for studies fulfilling pre-defined inclusion criteria.

RESULTS: 5085 records were identified, of which 66 were included in the analysis. These covered: Europe (n=18), Asia (n=17), Africa (n=13), North America (n=13), South America (n=4), and multi-regional (n=1). EQ-5D (n=37) and SF-36 (n=26) were the most used instrument, whilst SG, SF-6D, and HUI-3 were used in one study each. Among PLWH in high-income countries, the ranges of mean values of EQ-VAS scores and EQ-5D utility scores were 61.7-84.3 and 0.74-0.912, respectively. EQ-5D mean range was 0.56-0.89 in middle-income countries, while in low-income countries, one study reported a mean of 0.37 and another a median of 0.94. Six studies compared the EQ-5D scores for PLWH vs. general population; all except one reported significantly lower scores for PLWH than general population with a mean difference ranging from 0.01-0.08. HRQoL assessed using SF-36 scores were lower in patients with HIV compared to general population. Studies reporting HSUVs according to different sociodemographic factors suggested that older age, female gender, unemployment, and lower level of education and income were associated with lower utilities. Alternatively, longer disease and treatment duration had no impact on utilities.

CONCLUSIONS: Studies report a wide range of HSUVs in PLWH, which vary between countries. Many studies report lower utilities in PLWH compared to general population despite the success of ART. These post-ART collective estimates of HSUVs and their current trends need to be used carefully for economic evaluations in HIV.